1
|
Ma L, Ying Z, Cai W, Wang J, Zhou J, Yang H, Gao J, Zhao Z, Liu J, Ouyang S, Song S, Shen F, Zhao R, Xu L, Dai X, Wu Y, Li W, Li C, Liao G. Immune persistence of an inactivated poliovirus vaccine derived from the Sabin strain: a 10-year follow-up of a phase 3 study. EClinicalMedicine 2023; 64:102151. [PMID: 37745024 PMCID: PMC10514427 DOI: 10.1016/j.eclinm.2023.102151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/09/2023] [Revised: 07/24/2023] [Accepted: 07/25/2023] [Indexed: 09/26/2023] Open
Abstract
Background In a previous phase 3 clinical trial, we showed that an inactivated poliovirus vaccine derived from the Sabin strain (sIPV) can induce neutralising antibodies against currently circulating and reference wild poliovirus strains. However, the immune persistence of sIPV remains to be evaluated. Methods In this study, 400 participants who were eligible for an early phase 3 clinical trial (Jan 1, 2012-Aug 31, 2014) in Pingle County, GuanXi Province, China, were initially involved in one site. Of the participants in the previous phase 3 clinical trial, sera of 287, 262, 237, and 207 participants were sampled at the ages of 4, 6, 8, and 10 years, respectively, after the prime-boost regimen. Neutralising antibodies against attenuated Sabin strains were detected using these serum samples to determine immune persistence. The serum neutralising antibodies titre of 1:8 against poliovirus types 1, 2, and 3 is considered to be a seroprotection level for polio. The trial is registered at ClinicalTrials.gov, NCT01510366. Findings The protective rates against poliovirus types 1, 2, and 3 in the sIPV group were all 100% at 10 years after the booster immunisation, compared with 98.1%, 100%, and 97.1%, respectively, in the wIPV control group after 10 years. After the booster at 18 months, the geometric mean titres (GMTs) of neutralising antibodies against poliovirus types 1, 2, and 3 in the sIPV group were 13,265.6, 7856.7, and 6432.2, respectively, and the GMTs in the control group (inoculated with inactivated poliovirus vaccine derived from wild strain (wIPV)) were 3915.6, 2842.6, and 4982.7, respectively. With increasing time after booster immunisation, the GMTs of neutralising antibodies against poliovirus types 1, 2, and 3 gradually decreased in both the sIPV and wIPV groups. At the age of ten years, the GMTs of neutralising antibodies against poliovirus types 1, 2, and 3 in the sIPV group were 452.3, 392.8, and 347.5, respectively, and the GMTs in the wIPV group 108.5, 154.8, and 229.3, respectively, which were still at a higher-than-protective level (1:8). Interpretation Both sIPV and wIPV maintained sufficiently high immune persistence against poliovirus types 1, 2, and 3 for at least 10 years after booster immunisation. Funding Yunnan Provincial Science and Technology Department, the Bill and Melinda Gates Foundation, the National High-tech Research and Development Program, the National International Science and Technology Cooperation Project, the Yunnan Application Basic Research Project, the Innovation Team Project of Xie He, the Yunnan International Scientific and Technological Cooperation Project, and the Medical and Technology Innovation Project of Xie He.
Collapse
Affiliation(s)
- Lei Ma
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China
- Peking Union Medical College, Kunming, China
| | - Zhifang Ying
- National Institutes for Food and Drug Control, Beijing, China
| | - Wei Cai
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China
- Peking Union Medical College, Kunming, China
| | - Jianfeng Wang
- National Institutes for Food and Drug Control, Beijing, China
| | - Jian Zhou
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China
- Peking Union Medical College, Kunming, China
| | - Huijuan Yang
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China
- Peking Union Medical College, Kunming, China
| | - Jingxia Gao
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China
- Peking Union Medical College, Kunming, China
| | - Zhimei Zhao
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China
- Peking Union Medical College, Kunming, China
| | - Jing Liu
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China
- Peking Union Medical College, Kunming, China
| | - Shengjie Ouyang
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China
- Peking Union Medical College, Kunming, China
| | - Shaohui Song
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China
- Peking Union Medical College, Kunming, China
| | - Fei Shen
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China
- Peking Union Medical College, Kunming, China
| | - Ruirui Zhao
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China
- Peking Union Medical College, Kunming, China
| | - Lilan Xu
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China
- Peking Union Medical College, Kunming, China
| | - Xiaohu Dai
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China
- Peking Union Medical College, Kunming, China
| | - Yanan Wu
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China
- Peking Union Medical College, Kunming, China
| | - Weidong Li
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China
- Peking Union Medical College, Kunming, China
| | - Changgui Li
- National Institutes for Food and Drug Control, Beijing, China
| | - Guoyang Liao
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China
- Peking Union Medical College, Kunming, China
| |
Collapse
|
2
|
Shi L, Sun M. The progress of postapproval clinical studies on Sabin IPV. Hum Vaccin Immunother 2021; 18:1-4. [PMID: 34213408 PMCID: PMC8920192 DOI: 10.1080/21645515.2021.1940653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Abstract
As one of the powerful vaccines for completely eradicating all types of poliovirus in the polio endgame period, the novel IPV, which is prepared from attenuated polio Sabin strains (sIPV) and is expected to reduce the overall biosafety risk, was licensed in Japan (sIPV-containing diphtheria-tetanus-acellular pertussis combination vaccines, DTP-sIPV) and China (sIPV) in November 2012 and January 2015, respectively. Limited by the development progress and the manufactured sIPV ability, it has to date only been used in Chinese Expanded Programme on Immunization (EPI) by sequential scheduling with bOPV and in Japan with DTP-sIPV vaccination. We herein summarize postapproval clinical studies of sIPV in both full-dose schedules and sequential schedules, focusing on China, to evaluate sIPV safety and immunogenicity in large populations to provide important data for its broad application in developing countries worldwide.
Collapse
Affiliation(s)
- Li Shi
- Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming, Yunnan, China
| | - Mingbo Sun
- Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming, Yunnan, China.,Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, Yunnan, China
| |
Collapse
|
3
|
Immunogenicity and Safety of Inactivated Sabin-Strain Polio Vaccine "PoliovacSin": Clinical Trials Phase I and II. Vaccines (Basel) 2021; 9:vaccines9060565. [PMID: 34072466 PMCID: PMC8229617 DOI: 10.3390/vaccines9060565] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2021] [Revised: 05/23/2021] [Accepted: 05/24/2021] [Indexed: 11/23/2022] Open
Abstract
Global polio eradication requires both safe and effective vaccines, and safe production processes. Sabin oral poliomyelitis vaccine (OPV) strains can evolve to virulent viruses and result in poliomyelitis outbreaks, and conventional inactivated poliomyelitis vaccine (Salk-IPV) production includes accumulation of large stocks of neurovirulent wild polioviruses. Therefore, IPV based on attenuated OPV strains seems a viable option. To increase the global supply of affordable inactivated vaccine in the still not-polio free world we developed an IPV made from the Sabin strains–PoliovacSin. Clinical trials included participants 18–60 years of age. A phase I single-center, randomized, double-blind placebo-controlled clinical trial included 60 participants, who received one dose of PoliovacSin or Placebo. A phase II multicenter, randomized, double-blind, comparative clinical trial included 200 participants, who received one dose of PoliovacSin or Imovax Polio. All vaccinations were well tolerated, and PoliovacSin had a comparable safety profile to the Placebo or the reference Imovax Polio preparations. A significant increase in neutralizing antibody levels to polioviruses types 1–3 (Sabin and wild) was observed in PoliovacSin and Imovax Polio vaccinated groups. Therefore, clinical trials confirmed good tolerability, low reactogenicity, and high safety profile of the PoliovacSin and its pronounced immunogenic properties. The preparation was approved for clinical trials involving infants.
Collapse
|
4
|
Jiang R, Liu X, Sun X, Wang J, Huang Z, Li C, Li Z, Zhou J, Pu Y, Ying Z, Yin Q, Zhao Z, Zhang L, Lei J, Bao W, Jiang Y, Dou Y, Li J, Yang H, Cai W, Deng Y, Che Y, Shi L, Sun M. Immunogenicity and safety of the inactivated poliomyelitis vaccine made from Sabin strains in a phase IV clinical trial for the vaccination of a large population. Vaccine 2021; 39:1463-1471. [PMID: 33487470 DOI: 10.1016/j.vaccine.2021.01.027] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2020] [Revised: 01/08/2021] [Accepted: 01/09/2021] [Indexed: 11/29/2022]
Abstract
As a recently launched novel vaccine used as one of the vaccines for the final eradication of polios worldwide, complete data on the consistency and immunogenicity characteristics of the inactivated poliomyelitis vaccine made from the Sabin strain (sIPV) and its safety in large-scale populations are required to support the future use of this vaccine worldwide. A phase IV clinical trial was conducted to perform an immunogenicity evaluation of lot-to-lot consistency of three commercial batches of sIPV in 1200 infants and to investigate the vaccine's safety on a large-scale in 20,019 infants for active monitoring and 29,683 infants for passive monitoring through the Adverse Event Following Immunization (AEFI) reporting system in China. In the immunogenicity evaluation, the average seroconversion rates for type I, type II and type III of the three groups were 99.83%, 98.93% and 99.44%, respectively. No differences in the seroconversion rate and the GMT ratios were noted in the pair-to-pair comparisons. In the large-scale safety evaluation, most adverse reactions occurred 0-30 days after the first doses, and the common local and systemic reactions were similar to those in the phase III clinical trial, with low incidence in both activated and passive monitoring. In conclusion, sIPV exhibits good lot-to-lot consistency and safety in large-scale populations; thus, it is qualified to serve as one of the vaccines for use in eradicating all wild and vaccine-derived polioviruses worldwide in the near future. Clinic Trial Registration. NCT04224519 and NCT04220515.
Collapse
Affiliation(s)
- Ruiju Jiang
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, Yunnan, China; Yunnan Key Laboratory of Vaccine Research and Development on Severe Infections Diseases, Kunming, Yunnan, China
| | - Xiaoqiang Liu
- Vaccine Clinical Research Center, Yunnan Center for Disease Control and Prevention, Kunming, Yunnan, China
| | - Xiaodong Sun
- Shanghai Center for Disease Control and Prevention, Shanghai, China.
| | - Jianfeng Wang
- Division of Respiratory Virus Vaccines, National Institutes for Food and Drug Control, Beijing, China
| | - Zhuoying Huang
- Shanghai Center for Disease Control and Prevention, Shanghai, China.
| | - Changgui Li
- Division of Respiratory Virus Vaccines, National Institutes for Food and Drug Control, Beijing, China
| | - Zhi Li
- Shanghai Center for Disease Control and Prevention, Shanghai, China.
| | - Jianmei Zhou
- Mile Center for Disease Control and Prevention, Mile, Yunnan, China
| | - Yi Pu
- Gejiu Center for Disease Control and Prevention, Gejiu, Yunnan, China
| | - Zhifang Ying
- Division of Respiratory Virus Vaccines, National Institutes for Food and Drug Control, Beijing, China
| | - Qiongzhou Yin
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, Yunnan, China
| | - Zhimei Zhao
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, Yunnan, China
| | - Lifeng Zhang
- Vaccine Clinical Research Center, Yunnan Center for Disease Control and Prevention, Kunming, Yunnan, China
| | - Jing Lei
- Gejiu Center for Disease Control and Prevention, Gejiu, Yunnan, China
| | - Wenmei Bao
- Gejiu Center for Disease Control and Prevention, Gejiu, Yunnan, China
| | - Ya Jiang
- Mile Center for Disease Control and Prevention, Mile, Yunnan, China
| | - Youjian Dou
- Mile Center for Disease Control and Prevention, Mile, Yunnan, China
| | - Jingyu Li
- Vaccine Clinical Research Center, Yunnan Center for Disease Control and Prevention, Kunming, Yunnan, China
| | - Haitao Yang
- Vaccine Clinical Research Center, Yunnan Center for Disease Control and Prevention, Kunming, Yunnan, China
| | - Wei Cai
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, Yunnan, China; Yunnan Key Laboratory of Vaccine Research and Development on Severe Infections Diseases, Kunming, Yunnan, China.
| | - Yan Deng
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, Yunnan, China.
| | - Yanchun Che
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, Yunnan, China.
| | - Li Shi
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, Yunnan, China.
| | - Mingbo Sun
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, Yunnan, China; Yunnan Key Laboratory of Vaccine Research and Development on Severe Infections Diseases, Kunming, Yunnan, China.
| |
Collapse
|
5
|
Yan S, Chen H, Zhang Z, Chang S, Xiao Y, Luo L, Zhang Z, Sun L, Chen X, Yang Y, Shi X, Guo Y, Sun Y, Li H, Li N, Han S, Ma M, Yang X. Immunogenicity and safety of different sequential schedules of Sabin strain-based inactivated poliovirus vaccination: A randomized, controlled, open-label, phase IV clinical trial in China. Vaccine 2020; 38:6274-6279. [PMID: 32747216 DOI: 10.1016/j.vaccine.2020.07.042] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2020] [Revised: 07/16/2020] [Accepted: 07/20/2020] [Indexed: 11/16/2022]
Abstract
BACKGROUND The immunogenicity and safety of the sequential schedule of Sabin strain-based inactivated poliovirus vaccine (sIPV) and bivalent oral poliovirus vaccine (bOPV) remains poorly understood in Chinese population. METHODS A multi-center, open-label, randomized controlled trial was performed involving 648 healthy infants aged 2 months from Inner Mongolia, Shanxi, and Hebei provinces. These participants were divided into three groups: sIPV-bOPV-bOPV, sIPV-sIPV-bOPV, and sIPV-sIPV-sIPV. Doses were administered sequentially at age 2, 3, and 4 months. Neutralisation assays were tested using sera collected at 2 months and 5 months. RESULTS A total of 569 were included in the per-protocol analysis. The seroconversion rates of poliovirus type 1 and 3 were 100% in all three groups, the seroconversion rate of poliovirus type 2 was 91.53% (173/189) (95% CI: 86.62-95.08) in the sIPV-bOPV-bOPV group, 98.38% (182/185) (95% CI: 95.33-99.66) in the sIPV-sIPV-bOPV group, and 99.49% (194/195) (95% CI: 97.18-99.99) in the sIPV-sIPV-sIPV group. For the seroconversion rate of poliovirus types 1 and 3, the sIPV-bOPV-bOPV and sIPV-sIPV-bOPV groups were non-inferior to the sIPV-sIPV-sIPV group. For the seroconversion rate of poliovirus type 2, the sIPV-sIPV-bOPV group was non-inferior to the sIPV-sIPV-sIPV group, and the sIPV-bOPV-bOPV group was inferior to the sIPV-sIPV-sIPV group. All three groups exhibited good safety, with two serious adverse events reported, that were unrelated to vaccine. CONCLUSIONS In china, a new vaccination schedule that including 2 doses of IPV in the national immunization programs is essential. Trial registration ClinicalTrials.govNCT04054492.
Collapse
Affiliation(s)
- Shaohong Yan
- Inner Mongolia Autonomous Region Disease Prevention and Control Center, Huhhot, China
| | - Haiping Chen
- China National Biotec Group Company Limited, Beijing, China
| | - Zhenguo Zhang
- Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, China
| | - Shaoying Chang
- Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China
| | - Yanhui Xiao
- China National Biotec Group Company Limited, Beijing, China
| | - Linyun Luo
- China National Biotec Group Company Limited, Beijing, China
| | - Zhaoyong Zhang
- Inner Mongolia Autonomous Region Disease Prevention and Control Center, Huhhot, China
| | - Li Sun
- Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, China
| | - Xiao Chen
- Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China
| | - Yunkai Yang
- Beijing Institute of Biological Products Company Limited, Beijing, China
| | - Xuanwen Shi
- China National Biotec Group Company Limited, Beijing, China
| | - Yu Guo
- Inner Mongolia Autonomous Region Disease Prevention and Control Center, Huhhot, China
| | - Yunlong Sun
- Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, China
| | - Hong Li
- Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China
| | - Na Li
- Beijing Institute of Biological Products Company Limited, Beijing, China
| | - Shasha Han
- China National Biotec Group Company Limited, Beijing, China
| | - Meng Ma
- Beijing Institute of Biological Products Company Limited, Beijing, China
| | - Xiaoming Yang
- China National Biotec Group Company Limited, Beijing, China.
| |
Collapse
|
6
|
Arita M, Iwai-Itamochi M. Evaluation of antigenic differences between wild and Sabin vaccine strains of poliovirus using the pseudovirus neutralization test. Sci Rep 2019; 9:11970. [PMID: 31427704 PMCID: PMC6700111 DOI: 10.1038/s41598-019-48534-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2019] [Accepted: 08/07/2019] [Indexed: 12/16/2022] Open
Abstract
In the endgame of global polio eradication, serosurveillance is essential to monitor each country's vulnerability to poliomyelitis outbreaks. Previously, we developed pseudovirus poliovirus (PV) neutralization test (pPNT) with type 1, 2, and 3 PV pseudovirus (PVpv), which possess a luciferase-encoding PV replicon in the capsids of wild-type strains (PVpv[WT]), showing that pPNT with type 2 and 3 PVpv(WT) but not type 1 shows high correlation with the conventional PV neutralization test (cPNT) performed with vaccine strains. Here, we analyse the antigenicity of PVpv(WT) and PVpv with capsid proteins of Sabin vaccine strains (PVpv[Sabin]) in human serum. Type 2 and 3 PVpv(WT) and PVpv(Sabin) show similar antigenicity in the analysed set of human sera in contrast to type 1 PVpv. The levels of PVpv(Sabin) infection (%), including about 70% of PVpv infection (%) measured in the presence of human serum diluted to the cPNT titre, serve as the optimal threshold values for pPNT (5% for type 1 and 2, 10% for type 3) to show high correlation with cPNT results. Our results suggest that pPNT with PVpv(Sabin) could serve as an alternative to cPNT and provide a rationale for pPNT threshold values.
Collapse
Affiliation(s)
- Minetaro Arita
- Department of Virology II, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama-shi, Tokyo, 208-0011, Japan.
| | - Masae Iwai-Itamochi
- Department of Virology, Toyama Institute of Health, 17-1 Nakataikoyama, Imizu-shi, Toyama, 939-0363, Japan
| |
Collapse
|